尤其是在亚洲人群中，针对 LDL-C 降低药物基因的研究少之又少，这就好比在对抗冠心病的战场上，亚洲人群缺少关键的 “作战情报”。为了填补这一空白，来自韩国梨花女子大学首尔医院、蔚山大学医学院、亚洲大学医学中心等机构的研究人员，决定发起一场针对 LDL-C 降低药物靶点基因与冠心病关系的 “攻坚战”。他们的研究成果发表在了《Lipids in Health and Disease》杂志上。

在肝脏中对PCSK9进行表观遗传编辑，旨在诱导DNA甲基化和沉默基因表达，在表达人类PCSK9基因的转基因小鼠和食蟹猴中实现了LDL胆固醇水平的长期降低。 靶向人类 PCSK9 的强效表观遗传编辑器：降低低密度脂蛋白胆固醇水平的新突破 近日，来自 Chroma Medicine 的 ...

AstraZeneca has bought rights to an orally-active drug that inhibits PCSK9, offering a patient-friendly alternative to current cholesterol-lowering therapies that have to be delivered via a needle.

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that binds to the LDL receptor on hepatocytes, promoting its internalization and degradation within the cell. [Repatha package ...